Erste Asset Management GmbH acquired a new position in shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT – Free Report) in the 4th quarter, HoldingsChannel reports. The fund acquired 50,000 shares of the company’s stock, valued at approximately $360,000.
Several other institutional investors also recently bought and sold shares of EYPT. Patient Square Capital LP purchased a new stake in EyePoint Pharmaceuticals during the third quarter worth approximately $10,882,000. Franklin Resources Inc. lifted its position in shares of EyePoint Pharmaceuticals by 9.9% during the third quarter. Franklin Resources Inc. now owns 4,012,048 shares of the company’s stock worth $32,056,000 after purchasing an additional 362,399 shares in the last quarter. JPMorgan Chase & Co. lifted its position in shares of EyePoint Pharmaceuticals by 1,171.3% during the third quarter. JPMorgan Chase & Co. now owns 371,758 shares of the company’s stock worth $2,970,000 after purchasing an additional 342,516 shares in the last quarter. abrdn plc acquired a new position in shares of EyePoint Pharmaceuticals during the fourth quarter worth $1,719,000. Finally, Barclays PLC lifted its position in shares of EyePoint Pharmaceuticals by 410.4% during the third quarter. Barclays PLC now owns 245,045 shares of the company’s stock worth $1,959,000 after purchasing an additional 197,033 shares in the last quarter. 99.41% of the stock is currently owned by hedge funds and other institutional investors.
EyePoint Pharmaceuticals Price Performance
EYPT stock opened at $6.52 on Friday. EyePoint Pharmaceuticals, Inc. has a 1-year low of $5.54 and a 1-year high of $23.97. The firm has a fifty day moving average price of $7.19 and a two-hundred day moving average price of $8.39. The firm has a market cap of $448.11 million, a price-to-earnings ratio of -3.26 and a beta of 1.41.
Analysts Set New Price Targets
A number of research analysts have recently commented on EYPT shares. StockNews.com raised shares of EyePoint Pharmaceuticals to a “sell” rating in a research report on Friday. Citigroup initiated coverage on shares of EyePoint Pharmaceuticals in a research report on Tuesday, January 7th. They set a “buy” rating and a $33.00 target price on the stock. Chardan Capital reaffirmed a “buy” rating and issued a $33.00 price target on shares of EyePoint Pharmaceuticals in a report on Thursday, March 6th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $22.00 price target on shares of EyePoint Pharmaceuticals in a report on Thursday, March 6th. One analyst has rated the stock with a sell rating and nine have assigned a buy rating to the company’s stock. According to MarketBeat, EyePoint Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $26.63.
Read Our Latest Stock Report on EyePoint Pharmaceuticals
About EyePoint Pharmaceuticals
EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.
Featured Stories
- Five stocks we like better than EyePoint Pharmaceuticals
- What Are Growth Stocks and Investing in Them
- Ignore Reports, Apple Won’t Install Starlink with iOS 18.3
- What is the Nikkei 225 index?
- Casey’s Uptrend Remains Strong—New Highs on the Horizon
- Growth Stocks: What They Are, What They Are Not
- Taiwan Semiconductor’s Huge U.S. Move—Stock Impact Ahead
Want to see what other hedge funds are holding EYPT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT – Free Report).
Receive News & Ratings for EyePoint Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EyePoint Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.